ArticleACS pharmacology & translational science2019
Molecular Signatures of Fusion Proteins in Cancer.
Article in ACS pharmacology & translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 28 citations in OpenAlex.
- Targeting fusion proteins in solid tumors: from oncogenic mechanisms to clinical interventions.Acta pharmacologica Sinica · 2026Review
- Deregulated enhancer-promoter communication in cancer through altered nuclear architecture.International journal of cancer · 2026Review
- Molecular grammars of predicted intrinsically disordered regions that span the human proteome.Cell · 2026Article
- BCAM-AKT2 fusion protein promotes unfolded protein response driven oncogenic signaling in SKOV3 epithelial ovarian cancer cell line.PloS one · 2026Article
- Oncofusions - shaping cancer care.The oncologist · 2025Article
- Native and tagged CENP-A histones are functionally inequivalent.Epigenetics & chromatin · 2024Article
- Sequence variations of phase-separating proteins and resources for studying biomolecular condensates.Acta biochimica et biophysica Sinica · 2023Review
- The Landscape of Expressed Chimeric Transcripts in the Blood of Severe COVID-19 Infected Patients.Viruses · 2023Article
- Ectopic biomolecular phase transitions: fusion proteins in cancer pathologies.Trends in cell biology · 2022Review
- Oncogenic fusion proteins and their role in three-dimensional chromatin structure, phase separation, and cancer.Current opinion in genetics & development · 2022Review
- Article
- t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.Blood advances · 2022Article
- A review on interplay between small RNAs and oxidative stress in cancer progression.Molecular and cellular biochemistry · 2021Review
- Computational analysis of sense-antisense chimeric transcripts reveals their potential regulatory features and the landscape of expression in human cells.NAR genomics and bioinformatics · 2021Article
- Emerging Role of Chimeric RNAs in Cell Plasticity and Adaptive Evolution of Cancer Cells.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although gene fusions are recognized as driver mutations in a wide variety of cancers, the general molecular mechanisms underlying oncogenic fusion proteins are insufficiently understood. Here, we employ large-scale data integration and machine learning and (1) identify three functionally distinct subgroups of gene fusions and their molecular signatures; (2) characterize the cellular pathways rewired by fusion events across different cancers; and (3) analyze the relative importance of over 100 structural, functional, and regulatory features of ∼2200 gene fusions. We report subgroups of fusions that likely act as driver mutations and find that gene fusions disproportionately affect pathways regulating cellular shape and movement. Although fusion proteins are similar across different cancer types, they affect cancer type-specific pathways. Key indicators of fusion-forming proteins include high and nontissue specific expression, numerous splice sites, and higher centrality in protein-interaction networks. Together, these findings provide unifying and cancer type-specific trends across diverse oncogenic fusion proteins.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.